Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have been assigned an average recommendation of "Buy" from the seven research firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $11.00.

A number of research firms recently issued reports on AQST. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $17.00 price objective on the stock. Leerink Partners lifted their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. JMP Securities restated a "market outperform" rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics in the third quarter worth about $995,000. Blue Owl Capital Holdings LP boosted its stake in Aquestive Therapeutics by 30.3% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company's stock worth $2,964,000 after purchasing an additional 265,000 shares during the period. Bank of New York Mellon Corp purchased a new stake in Aquestive Therapeutics during the 2nd quarter valued at approximately $594,000. Wellington Management Group LLP bought a new stake in shares of Aquestive Therapeutics during the third quarter valued at approximately $922,000. Finally, Chartwell Investment Partners LLC bought a new stake in shares of Aquestive Therapeutics during the third quarter valued at approximately $535,000. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Stock Performance

Shares of AQST stock traded up $0.01 on Friday, reaching $3.65. The stock had a trading volume of 1,344,092 shares, compared to its average volume of 1,739,676. Aquestive Therapeutics has a 1 year low of $1.84 and a 1 year high of $6.23. The stock has a market cap of $332.80 million, a P/E ratio of -8.11 and a beta of 2.62. The company has a 50 day simple moving average of $4.71 and a 200 day simple moving average of $4.08.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same quarter last year, the firm earned ($0.03) earnings per share. On average, equities research analysts anticipate that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.